ABBOTT LABORATORIES Funds and ETFs Abbott Laboratories
Equities
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103 USD | -0.24% |
|
-1.01% | -6.46% |
| May. 15 | Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit | MT |
| May. 09 | Drugmaker Abbott India posts Q4 profit rise on higher sales | RE |
ETFs positioned on Abbott Laboratories
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.55% | 9 M€ | +10.64% | ||
| 0.55% | 5 M€ | -.--% | - | |
| 0.52% | 2,517 M€ | +13.43% | - | |
| 0.50% | 1,006 M€ | -.--% | - | |
| 0.50% | 414 M€ | +13.03% | - | |
| 0.49% | 7 M€ | +6.22% | - | |
| 0.49% | 57 M€ | +22.73% | - | |
| 0.49% | 205 M€ | -.--% | ||
| 0.48% | 322 M€ | +13.88% | - | |
| 0.48% | 29 M€ | -.--% | - | |
| 0.48% | 1 M€ | -.--% | ||
| 0.47% | 7 M€ | +0.11% | - | |
| 0.45% | 34 M€ | +12.87% | - | |
| 0.41% | 727 M€ | +9.56% | ||
| 0.40% | 25 M€ | +4.74% | - | |
| 0.40% | 283 M€ | +21.53% | ||
| 0.39% | 14 M€ | +16.19% | - | |
| 0.39% | 284 M€ | -.--% | ||
| 0.38% | 234 M€ | +7.12% | - | |
| 0.38% | 23 M€ | -.--% | - | |
| 0.38% | 786 M€ | -.--% | ||
| 0.37% | 50 M€ | +11.42% | ||
| 0.36% | 206 M€ | -.--% | ||
| 0.33% | 1 M€ | +3.03% | - | |
| 0.32% | 607 M€ | +0.05% | - |
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows:
- diagnostic systems and instruments (39.1%);
- vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (15.9%).
Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Calendar
2024-07-17
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
103
USD
Average target price
126.1
USD
Spread / Average Target
+22.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.46% | 180B | |
| +3.39% | 112B | |
| -3.68% | 68.53B | |
| +5.44% | 51.97B | |
| +5.70% | 44.08B | |
| +4.37% | 42.23B | |
| +25.42% | 32.43B | |
| +14.52% | 26.39B | |
| -4.29% | 24.97B | |
| -2.22% | 24.49B |
- Stock Market
- Equities
- ABT Stock
- Funds and ETFs Abbott Laboratories